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Background
Kaposi sarcoma (KS) flare (exacerbation) may occur fol-
lowing therapy with corticosteroids, as part of the
immune reconstitution inflammatory syndrome seen
with highly active antiretroviral therapy (HAART), and
after rituximab therapy. The exact mechanism responsible
for iatrogenic KS flare is unclear. Therefore, the aim of this
study was to investigate the pathologic features in cases of
AIDS-associated KS flare.
Methods
Two cases of AIDS-associated cutaneous KS flare were
identified following rituximab therapy. Tissue biopsies
obtained from these KS flare lesions were compared to
similar controls (AIDS-KS samples of similar stage from
patients who had not received rituximab) by means of
immunohistochemistry using vascular makers (CD34,
CD31), monoclonal antibodies to human Herpesvirus-8
(HHV-8) gene products (LNA-1, K5), as well as B-lym-
phocyte (CD20) and T-lymphocyte (CD3, CD4, CD8)
markers.
Results
One patient was a 36-year-old male, HIV-positive for 2
years (CD4 T-lymphocyte count 363 cells/mm3; HIV viral
load >100,000 copies/ml), and the other a 44-year-old
male, HIV-positive for 5 years (CD4 T-lymphocyte count
443 cells/mm3; HIV viral load <75 copies/ml), who had
both received rituximab therapy for multicentric Castle-
man disease. The former manifested with cutaneous KS
after 7 days, and the later patient with skin and lymphad-
enopathic KS flares within 3 months of receiving rituxi-
mab. In the control cases both CD3 and CD20 cells were
present, with a preponderance of T-lymphocytes identi-
fied. In the KS flare specimens, there were only T-cells
present with a notable absence of B-lymphocytes. In all
control and flare KS cases T-cell subsets showed CD8 >
CD4. CD20+ B-cell depletion in the KS flare case of the
36-year-old patient occurred concomitantly with activa-
tion of the HHV-8 immediate early gene protein K5. KS
flares in both patients were successfully treated with lipo-
somal doxorubicin and valganciclovir.
Conclusion
Rituximab-induced KS flare appears to be related to a
modification in the host immune system, most notably
with complete absence of B lymphocytes in the KS lesion.
B-cell depletion with rituximab in patients at risk for KS
development may activate HHV-8, resulting in unwanted
KS flare. Effective management of iatrogenic KS flare
therefore depends upon the control of HHV-8 viremia in
conjunction with specific chemotherapy for KS.
from 11th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI): Basic, Epidemiologic, and Clinical 
Research
Bethesda, MD, USA. 6–7 October 2008
Published: 17 June 2009
Infectious Agents and Cancer 2009, 4(Suppl 2):P33 doi:10.1186/1750-9378-4-S2-P33
<supplement> <title> <p>Proceedings of the 11th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI): Basic, Epidemiologic, and Clinical Research</p> </title> <sponsor> <note>Publication of this supplement was made possible with support from the Office of HIV and AIDS Malignancy, National Cancer Institute, National Institutes of Health.</note> </sponsor> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1750-9378-4-S2-full.pdf">here</a>.</note>  <url>http://www.biomedcentral.com/content/pdf/1750-9378-4-S2-info.pdf</url> </supplement>
This abstract is available from: http://www.infectagentscancer.com/content/4/S2/P33
© 2009 Pantanowitz et al; licensee BioMed Central Ltd. 